search for




 

Factors Associated with Length of Hospital Stay in Pediatric Hematopoietic Stem Cell Transplantation Patients Administrating Parenteral Nutrition
정맥영양요법을 시행한 조혈모세포이식 소아의 재원기간에 영향을 미치는 인자
THE KOREAN SOCIETY FOR PARENTERAL AND ENTERAL NUTRITION 2011;4:1-6
Published online December 1, 2011
© 2011 The Korean Society for Parenteral and Enteral Nutrition.

Hyo Jung Park, R.Ph., Jung A Yoon, R.Ph., Do Young Kim, R.Ph., Yoon Jung Huh, R.Ph., Seon Young Chung, R.Ph., M.S., Yong Won In, R.Ph., M.S., Young Mee Lee, R.Ph., M.S., Jeong Meen Seo, M.D., Ph.D.1, Kie Ho Sohn, R.Ph., Ph.D.2
박효정ㆍ윤정아ㆍ김도영ㆍ허윤정ㆍ정선영ㆍ인용원ㆍ이영미ㆍ서정민1ㆍ손기호2

Pharmaceutical Services, 1Department of Surgery, Samsung Medical Center, Seoul, 2Department of Pharmacy, Kyungsung University, Busan, Korea
삼성서울병원 약제부, 1외과, 2경성대학교 약학대학
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Purpose: Parenteral nutrition (PN) is a standard supportive care for pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) in Samsung Medical Center. The objective of this study was to identify the factors associated with the length of hospital stay (LOS) in pediatric HSCT patients administrating PN routinely.
Methods: This was a retrospective study for 128 pediatric HSCT patients from Aug. 2008 to Dec. 2009. Demographics, nutrition status on the first report in the nutrition support team, calories and nutrients supplied, PN duration, LOS, PN-induced complications, and laboratory data were collected from electronic medical records. Multivariate analyses were conducted to identify factors associated with LOS.
Results: The median age of registered patients was 70 months (range 6∼239 months). Twenty-three patients (18.0%) were malnourished moderately to severely when PN was started. Number of autologous HSCT was larger than allogeneic HSCT (87 vs 41). In children undergoing HSCT, LOS was significantly correlated with PN duration (P<0.001) and graft type (P<0.001). Especially, in autologous peripheral blood stem cell transplantation (PBSCT), malnourished patients at the beginning of PN were shown the tendency to increase LOS (P=0.024) and PN duration (P=0.043).
Conclusion: In pediatric HSCT patients administrating PN routinely, LOS was associated with a graft type of HSCT and PN duration. Especially for autologous PBSCT patients, the nutrition status at the beginning of PN had the influence on LOS and PN duration. During the peri-HSCT period, careful nutrition monitoring can prevent malnutrition, decrease PN duration, and shorten LOS. (JKSPEN 2011;4(1):1-6)
Keywords : Pediatric, HSCT, PN, LOS
References
  1. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Michael posey L. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York:McGraw-Hill;2008.
  2. Helen Leather. HSCT and BMT Part I. page 361-434 2008 Oncology Pharmacy Preparatory Review Course American Society of Heath-System Pharmacists, Inc. Oncology Pharmacy Preparatory Review Course. ACCP. 2009.
  3. Sung KW, Yoo KH, Cho EJ, Koo HH, Lim DH, Shin HJ, et al. High-dose chemotherapy and autologouslogous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007;48(4):408-15.
    Pubmed CrossRef
  4. P?rez-Mart?nez A, Lassaletta A, Gonz?lez-Vicent M, Sevilla J, D?az MA, Madero L. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neurooncol 2005;71(1):33-8.
    Pubmed CrossRef
  5. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341(16):1165-73.
    Pubmed CrossRef
  6. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma:a randomised controlled trial. Lancet Oncol 2005;6(9):649-58.
    CrossRef
  7. Sung KW, Yoo KH, Chung EH, Jung HL, Koo HH, Shin HJ, et al. Successive double high-dose chemotherapy with peripheral blood stem cell rescue collected during a single leukapheresis round in patients with high-risk pediatric solid tumors:a pilot study in a single center. Bone Marrow Transplant 2003;31(6):447-52.
    Pubmed CrossRef
  8. Charuhas PM, Lipkin A, Lenssen P, McMillen K. Hematopoietic stem cell transplantatin. In: Merritt R eds. The A.S.P.E.N. nutrition support practice manual. 2nd ed. Silver Spring:American Society for Parenteral and Enteral Nutrition;2005:187-99.
  9. Han-Markey T. Nutritional considerations in pediatric oncology. Semin Oncol Nurs 2000;16(2):146-51.
    Pubmed CrossRef
  10. Geibig CB, Owens JP, Mirtallo JM, Bowers D, NahikianNelms M, Tutschka P. Parenteral nutrition for marrow transplant recipients: evaluation of an increased nitrogen dose. JPEN J Parenter Enteral Nutr 1991;15(2):184-8.
    Pubmed CrossRef
  11. Weisdorf SA, Lysne J, Wind D, Haake RJ, Sharp HL, Goldman A, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987;43(6):833-8.
    Pubmed CrossRef
  12. August DA, Huhmann MB; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009;33(5):472-500.
    Pubmed CrossRef
  13. Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972;3(5826):566-9.
    Pubmed KoreaMed CrossRef
  14. Weisdorf SA, Lysne J, Wind D, Haake RJ, Sharp HL, Goldman A, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987;43(6):833-8.
    Pubmed CrossRef
  15. Arfons LM, Lazarus HM. Total parenteral nutrition and hematopoietic stem cell transplantation: an expensive placebo? Bone Marrow Transplant 2005;36(4):281-8.
    Pubmed CrossRef
  16. Wedrychowicz A, Spodaryk M, Krasowska-Kwiecie? A, Go?dzik J. Total parenteral nutrition in children and adolescents treated with high-dose chemotherapy followed by autologous haematopoietic transplants. Br J Nutr 2010;103(6):899906.
    Pubmed CrossRef

 

June 2018, 10 (1)